PL1776142T4 - Przeciwciała antagonistyczne wobec IL-17 - Google Patents

Przeciwciała antagonistyczne wobec IL-17

Info

Publication number
PL1776142T4
PL1776142T4 PL05770286T PL05770286T PL1776142T4 PL 1776142 T4 PL1776142 T4 PL 1776142T4 PL 05770286 T PL05770286 T PL 05770286T PL 05770286 T PL05770286 T PL 05770286T PL 1776142 T4 PL1776142 T4 PL 1776142T4
Authority
PL
Poland
Prior art keywords
antagonistic antibodies
antagonistic
antibodies
Prior art date
Application number
PL05770286T
Other languages
English (en)
Polish (pl)
Other versions
PL1776142T6 (pl
PL1776142T3 (pl
Inventor
Franco E. Di Padova
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Wim Van Den Berg
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1776142(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1776142T3 publication Critical patent/PL1776142T3/pl
Publication of PL1776142T6 publication Critical patent/PL1776142T6/pl
Publication of PL1776142T4 publication Critical patent/PL1776142T4/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05770286T 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17 PL1776142T4 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
PCT/EP2005/008470 WO2006013107A1 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies
EP05770286.2A EP1776142B9 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies

Publications (3)

Publication Number Publication Date
PL1776142T3 PL1776142T3 (pl) 2011-12-30
PL1776142T6 PL1776142T6 (pl) 2016-06-30
PL1776142T4 true PL1776142T4 (pl) 2018-04-30

Family

ID=32982602

Family Applications (4)

Application Number Title Priority Date Filing Date
PL05770286T PL1776142T4 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17
PL10175150T PL2364729T6 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne IL-17
PL10174725T PL2366405T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne interleukiny IL-17
PL15156029T PL2902039T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL10175150T PL2364729T6 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne IL-17
PL10174725T PL2366405T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne interleukiny IL-17
PL15156029T PL2902039T3 (pl) 2004-08-05 2005-08-04 Przeciwciała antagonistyczne wobec IL-17

Country Status (40)

Country Link
US (9) US7807155B2 (enExample)
EP (5) EP2364729B3 (enExample)
JP (1) JP4682200B2 (enExample)
KR (2) KR100852523B1 (enExample)
CN (1) CN101001645B (enExample)
AR (1) AR050200A1 (enExample)
AT (1) ATE517924T1 (enExample)
AU (2) AU2005268857C1 (enExample)
BE (1) BE2015C041I2 (enExample)
BR (3) BR122017009404B1 (enExample)
CA (1) CA2573586C (enExample)
CY (6) CY1111963T1 (enExample)
DK (4) DK1776142T6 (enExample)
EC (1) ECSP077198A (enExample)
ES (4) ES2536228T3 (enExample)
FR (1) FR15C0048I2 (enExample)
GB (1) GB0417487D0 (enExample)
HK (1) HK1256639A1 (enExample)
HR (3) HRP20110758T4 (enExample)
HU (4) HUE038187T2 (enExample)
IL (1) IL180717A (enExample)
LT (3) LT2902039T (enExample)
LU (2) LU92768I2 (enExample)
MA (1) MA28982B1 (enExample)
MX (1) MX2007001338A (enExample)
MY (1) MY144925A (enExample)
NL (1) NL300749I2 (enExample)
NO (9) NO336279B1 (enExample)
NZ (1) NZ552658A (enExample)
PE (1) PE20060418A1 (enExample)
PL (4) PL1776142T4 (enExample)
PT (4) PT2366405E (enExample)
RU (2) RU2426741C3 (enExample)
SG (1) SG155186A1 (enExample)
SI (4) SI1776142T1 (enExample)
TN (1) TNSN07034A1 (enExample)
TR (1) TR201808057T4 (enExample)
TW (1) TWI359153B (enExample)
WO (1) WO2006013107A1 (enExample)
ZA (1) ZA200700242B (enExample)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP2322219A3 (en) * 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
LT2481753T (lt) * 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
MX2008007682A (es) 2005-12-20 2008-10-23 Sbi Biotech Co Ltd Anticuerpo anti-ilt7.
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
RU2430110C2 (ru) * 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
CA2660463C (en) 2006-08-11 2013-07-16 Schering Corporation Antibodies to il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
KR101591533B1 (ko) 2007-05-29 2016-02-03 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
CN101932935A (zh) * 2007-06-20 2010-12-29 先灵公司 用于炎性关节病抗白介素-17a治疗的关节破坏生物标记
EP2182943B1 (en) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2009072802A2 (en) * 2007-12-03 2009-06-11 Amorepacific Corporation Composition for slimming
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2242504B1 (en) 2008-01-09 2021-07-14 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
MX2010011309A (es) * 2008-04-29 2010-12-14 Micromet Ag Inhibidores de gm-csf e il-17 para terapia.
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
AR072000A1 (es) 2008-06-03 2010-07-28 Abbott Lab Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
KR101318549B1 (ko) * 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
EA027071B1 (ru) * 2009-04-27 2017-06-30 Новартис Аг АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
US8137671B2 (en) 2009-05-05 2012-03-20 Genentech, Inc. Anti-IL-17F antibodies
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012005086A (es) 2009-10-30 2012-09-28 Janssen Biotech Inc Antagonistas de il-17a.
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013537414A (ja) * 2010-08-05 2013-10-03 アナプティスバイオ インコーポレイティッド Ｉｌ−１７に対する抗体
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
PT2625199T (pt) 2010-10-08 2018-02-28 Novartis Ag Métodos de tratamento de psoríase usando antagonistas de il-17
BR112013011176A2 (pt) * 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
AU2014259526B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating ankylosing spondylitis using IL-17 antagonists
AR084234A1 (es) 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US20140004540A1 (en) * 2011-01-13 2014-01-02 Universite Paris Descartes Methods and kits for predicting the risk of having a cardiovascular event in a subject
ME02734B (me) 2011-01-14 2017-10-20 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
DK2691411T3 (da) 2011-03-29 2020-05-11 Glaxosmithkline Llc Buffersystem til proteinoprensning
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
AU2012341081B2 (en) * 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834273B1 (en) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
JP2015519311A (ja) 2012-04-20 2015-07-09 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて強直性脊椎炎を治療する方法
LT2852615T (lt) 2012-05-22 2019-02-11 Bristol-Myers Squibb Company Il-17a/f il-23 bispecifiniai antikūnai ir jų panaudojimai
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
SI2953969T1 (sl) 2013-02-08 2020-01-31 Novartis Ag Protitelesa proti-IL-17A in njihova uporaba v zdravljenju avtoimunskih in vnetnih motenj
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
CN105705518A (zh) 2013-08-30 2016-06-22 塔科达有限责任公司 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015070697A1 (zh) * 2013-11-18 2015-05-21 上海恒瑞医药有限公司 Il-17a结合物及其用途
KR20160113268A (ko) * 2014-01-28 2016-09-28 베이징 한미 파마슈티컬 컴퍼니 리미티드 이기능 융합단백질,이의 제조방법 및 용도
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
SMT202400285T1 (it) 2014-09-10 2024-09-16 Novartis Ag Uso di antagonisti di il-17 per inibire la progressione del danno strutturale in pazienti affetti da artrite psoriasica
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
PT3245224T (pt) 2015-01-12 2020-10-08 Affibody Ab Polipéptidos de ligação a il-17a
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN105315371B (zh) * 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 抗人il-17单克隆抗体
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016294332A1 (en) 2015-07-16 2017-11-30 Eli Lilly And Company Treatment of pruritus
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
IL257723B2 (en) 2015-10-19 2023-04-01 Novartis Ag Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
US11072652B2 (en) 2016-03-10 2021-07-27 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
HRP20241557T1 (hr) 2016-03-10 2025-05-23 Acceleron Pharma Inc. Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
WO2018015880A1 (en) 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
BR112019004990A2 (pt) 2016-09-14 2019-06-04 Beijing hanmi pharm co ltd anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
WO2018096467A1 (en) 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
CN110494453B (zh) 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
CA3080665A1 (en) 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17) antagonists
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
WO2019191563A1 (en) * 2018-03-29 2019-10-03 Remd Biotherapeutics, Inc. Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)
CN110551215A (zh) * 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
KR20250151605A (ko) 2018-06-01 2025-10-21 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
WO2020064702A1 (en) 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
IL320091A (en) 2019-01-31 2025-06-01 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
MY205369A (en) 2019-07-26 2024-10-17 Sinocelltech Ltd Humanized anti-il17a antibody and use thereof
EP4006053A4 (en) 2019-07-30 2022-10-26 Jiangsu Hengrui Medicine Co., Ltd. METHOD OF TREATMENT OF AUTOIMMUNE DISEASE BY IL-17 ANTAGONISTS
BR112022004941A2 (pt) 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
JP7093940B2 (ja) * 2019-09-25 2022-07-01 国立大学法人 東京大学 全身性強皮症治療用医薬組成物
ES3031715T3 (en) 2019-09-30 2025-07-10 Janssen Pharmaceutica Nv Compositions and methods for an il-17 target engagement assay with large molecule modulators
IL292926A (en) 2019-11-19 2022-07-01 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
CN114746444A (zh) 2019-12-06 2022-07-12 诺华股份有限公司 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
JP2023531497A (ja) 2020-06-23 2023-07-24 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して甲状腺眼疾患及びグレーブス眼窩症を治療する方法
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
EP4255927A1 (en) 2020-12-02 2023-10-11 Fresenius Kabi Deutschland GmbH Methods of selectively reducing antibodies
JP2023554489A (ja) 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
KR20250005308A (ko) 2022-04-25 2025-01-09 노파르티스 아게 Il-17 억제제의 결정질 형태
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
CA3257386A1 (en) 2022-05-18 2023-11-23 Novartis Ag METHOD FOR TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
KR20240141083A (ko) 2023-03-17 2024-09-25 (주)셀트리온 안정한 약제학적 제제 및 완제의약품의 제조공정
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
GB202407664D0 (en) 2024-05-30 2024-07-17 Fresenius Kabi Deutschland Gmbh Post-translational control of recombiant proteins
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
JP4373495B2 (ja) 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
EP0839196B1 (en) * 1995-07-19 2005-05-11 Genetics Institute, LLC Human ctla-8 and uses of ctla-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
PT862454E (pt) 1995-10-27 2002-11-29 Inst Nat La Sante Et La Rech M Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
DE69739375D1 (de) 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
AU9482498A (en) 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
JP4620243B2 (ja) 1997-11-10 2011-01-26 サイティミューン サイエンシーズ， インコーポレイテッド 生物学的に活性な因子の標的化された送達のための組成物および方法
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
JP2003502006A (ja) 1998-01-09 2003-01-21 イミュネックス・コーポレーション Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
AU2031399A (en) 1998-01-09 1999-07-26 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
JP2002503461A (ja) 1998-02-11 2002-02-05 マキシジェン， インコーポレイテッド 遺伝子ワクチンベクター工学
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
DK1114156T3 (da) 1998-09-17 2008-03-03 Zymogenetics Inc Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
PT1141297E (pt) 1999-01-11 2010-01-06 Schering Corp Citoquinas de mamíferos relacionadas com a interleucina-17. polinucleótidos que as codificam. utilizações
AU3207000A (en) 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
AU776790B2 (en) 1999-02-12 2004-09-23 Lexigen Pharmaceuticals Corporation Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
AU6677000A (en) 1999-08-27 2001-03-26 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
DE60143798D1 (de) 2000-06-16 2011-02-17 Cambridge Antibody Tech Immunspezifisch bindende antikörper gegen blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002033083A2 (en) 2000-10-13 2002-04-25 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
JP2004517918A (ja) * 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
ES2360481T3 (es) 2001-01-25 2011-06-06 Zymogenetics, Inc. Procedimiento para tratar psoriasis usando un antagonista de il- 17d.
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
MXPA05012571A (es) * 2003-05-21 2006-02-08 Medarex Inc Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
AU2004292393C1 (en) 2003-11-21 2011-08-04 Ucb Pharma S.A. Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
WO2005108616A1 (en) * 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2322219A3 (en) * 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
BE2015C041I2 (enExample) 2024-10-08
PT2366405E (pt) 2015-06-30
BRPI0513078C1 (pt) 2021-05-25
TR201808057T4 (tr) 2018-06-21
NO348010B1 (no) 2024-06-17
KR20070036166A (ko) 2007-04-02
EP2902039A1 (en) 2015-08-05
BRPI0513078B1 (pt) 2019-02-19
SI2364729T1 (sl) 2014-08-29
ES2677245T3 (es) 2018-07-31
CA2573586C (en) 2013-06-25
HRP20181069T1 (hr) 2018-09-07
CY1116256T1 (el) 2017-02-08
NO20151787L (no) 2006-02-06
EP3409288A1 (en) 2018-12-05
PL2364729T6 (pl) 2016-06-30
TNSN07034A1 (en) 2008-06-02
TW200617025A (en) 2006-06-01
CN101001645A (zh) 2007-07-18
BRPI0513078A (pt) 2008-04-22
RU2426741C3 (ru) 2017-11-15
US10344084B2 (en) 2019-07-09
NO20150064L (no) 2007-03-30
AU2005268857C1 (en) 2012-01-19
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
TWI359153B (en) 2012-03-01
PL1776142T6 (pl) 2016-06-30
CA2573586A1 (en) 2006-02-09
MX2007001338A (es) 2008-03-11
HK1101277A1 (en) 2007-10-12
ECSP077198A (es) 2007-02-28
SI2902039T1 (en) 2018-07-31
LU92768I2 (fr) 2015-11-03
ES2487533T3 (es) 2014-08-21
US8617552B2 (en) 2013-12-31
ZA200700242B (en) 2008-08-27
NO337129B1 (no) 2016-01-25
MY144925A (en) 2011-11-30
CY2015030I1 (el) 2015-11-04
ES2367440T7 (es) 2015-07-14
LT2902039T (lt) 2018-06-25
ATE517924T1 (de) 2011-08-15
DK2902039T3 (en) 2018-07-16
RU2011113153A (ru) 2012-10-20
DK1776142T3 (da) 2011-10-31
US8119131B2 (en) 2012-02-21
AU2010201689A1 (en) 2010-05-20
LUC00088I2 (enExample) 2018-12-17
NO2016017I1 (no) 2016-08-23
EP1776142A1 (en) 2007-04-25
US20120107325A1 (en) 2012-05-03
PL1776142T3 (pl) 2011-12-30
PT2902039T (pt) 2018-07-17
HUS1500037I1 (hu) 2017-10-30
BR122018075556B1 (pt) 2022-10-18
AU2005268857A1 (en) 2006-02-09
HK1256639A1 (en) 2019-09-27
EP2364729B1 (en) 2014-05-14
BR122017009404B1 (pt) 2022-02-22
LTC1776142I2 (lt) 2022-07-11
HUS1800040I1 (hu) 2018-11-28
LTPA2015029I1 (lt) 2022-07-11
PL2902039T3 (pl) 2018-09-28
DK2364729T3 (da) 2014-07-21
CN101001645B (zh) 2012-09-05
KR100852523B9 (ko) 2025-03-28
AR050200A1 (es) 2006-10-04
US20150152178A1 (en) 2015-06-04
US9765140B2 (en) 2017-09-19
WO2006013107A1 (en) 2006-02-09
NO2015023I1 (no) 2015-11-02
DK2364729T6 (en) 2015-07-06
AU2005268857B8 (en) 2010-05-27
US7807155B2 (en) 2010-10-05
NO341384B1 (no) 2017-10-30
NZ552658A (en) 2009-11-27
EP2364729A2 (en) 2011-09-14
LTPA2018515I1 (lt) 2018-10-25
US20190270804A1 (en) 2019-09-05
KR20080029018A (ko) 2008-04-02
ES2487533T7 (es) 2015-07-14
PT1776142E (pt) 2011-10-06
SG155186A1 (en) 2009-09-30
ES2367440T3 (es) 2011-11-03
CY2018027I2 (el) 2020-05-29
IL180717A0 (en) 2007-06-03
AU2005268857B2 (en) 2010-01-28
US20170355762A1 (en) 2017-12-14
HRP20110758T1 (en) 2011-11-30
PL2366405T3 (pl) 2015-08-31
NO20070985L (no) 2007-03-30
HUE038187T2 (hu) 2018-10-29
EP2366405A2 (en) 2011-09-21
EP1776142B3 (en) 2015-06-24
FR15C0048I2 (fr) 2015-11-20
PT2364729E (pt) 2014-09-01
AU2010201689B2 (en) 2011-09-29
EP2364729A3 (en) 2012-01-18
SI2366405T1 (sl) 2015-07-31
US20090280131A1 (en) 2009-11-12
EP1776142B1 (en) 2011-07-27
DK2366405T3 (en) 2015-05-11
CY2015030I2 (el) 2017-11-14
PL2364729T3 (pl) 2014-10-31
MA28982B1 (fr) 2007-11-01
PE20060418A1 (es) 2006-06-15
NL300749I2 (nl) 2017-11-02
RU2426741C2 (ru) 2011-08-20
NO20171697A1 (no) 2007-03-30
KR100852523B1 (ko) 2008-08-14
NO336279B1 (no) 2015-07-06
CY1115444T1 (el) 2017-01-04
IL180717A (en) 2012-07-31
FR15C0048I1 (fr) 2015-08-28
JP4682200B2 (ja) 2011-05-11
US20250122277A1 (en) 2025-04-17
NO2018007I1 (no) 2018-02-14
US20140079719A1 (en) 2014-03-20
DK1776142T6 (en) 2015-07-06
US20230235038A1 (en) 2023-07-27
CY1111963T1 (el) 2015-11-04
HUE025815T2 (en) 2016-04-28
JP2008507988A (ja) 2008-03-21
US20100215666A1 (en) 2010-08-26
HRP20150480T1 (hr) 2015-07-17
SI1776142T1 (sl) 2011-11-30
ES2536228T3 (es) 2015-05-21
CY1120723T1 (el) 2019-12-11
ES2367440T9 (es) 2021-04-28
EP2366405B1 (en) 2015-02-25
HK1207559A1 (en) 2016-02-05
HRP20110758T4 (hr) 2015-07-31
CY2018027I1 (el) 2020-05-29
EP2902039B1 (en) 2018-04-11
NO2015023I2 (no) 2015-10-26
EP2364729B3 (en) 2015-06-24
BRPI0513078B8 (pt) 2019-08-27
EP1776142B9 (en) 2016-09-07
NO337286B1 (no) 2016-02-29
GB0417487D0 (en) 2004-09-08
EP2366405A3 (en) 2012-01-18
NO20150065L (no) 2007-03-30

Similar Documents

Publication Publication Date Title
HUS1800040I1 (hu) IL-17 antagonista antitestek
IL181575A0 (en) Anti-ox40l antibodies
IL228032A0 (en) Antibodies
IL237756A0 (en) Antibody compositions
IL179672A0 (en) Anti-cd3 antibodies
IL197158A0 (en) Antagonistic human light-specific human monoclonal antibodies
IL182554A0 (en) Anti-addl antibodies and uses thereof
GB0420466D0 (en) Anti-glucan antibodies
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
ZA200701952B (en) Anti-OX40L antibodies
ZA200901165B (en) Antagonistic human light-specific human monoclonal antibodies
GB0413257D0 (en) Backpack
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
GB0418415D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0402641D0 (en) Antibodies
GB0402642D0 (en) Antibodies
GB0413479D0 (en) Novel antibodies
GB0413446D0 (en) Spot-on